

# T3204 Population Pharmacokinetic Evaluation of Eslicarbazepine Acetate for Adjunctive Therapy in Refractory Partial Onset Seizures

Qiang Lu<sup>2</sup>, Elizabeth Ludwig<sup>2</sup>, Jill Fiedler-Kelly<sup>2</sup>, Gary Maier<sup>1</sup>, David Blum<sup>1</sup>, Jahnvi Kharidia<sup>1</sup>  
<sup>1</sup>Sunovion Pharmaceuticals Inc, Marlborough, MA, USA; <sup>2</sup>Cognigen Corporation, Buffalo, NY, USA

## Abstract

**Purpose:** Eslicarbazepine acetate (ESL) is a once-daily antiepileptic drug (AED) that is converted to eslicarbazepine, the primary active metabolite of ESL, after oral administration. A population pharmacokinetic (PK) model for eslicarbazepine was developed and the influence of selected covariates and concomitant antiepileptics was investigated.

**Methods:** Multiple ESL doses of 400-1200 mg administered once daily were studied. Modeling was performed with full-profile and sparse data from 224 subjects in eleven Phase 1 studies (4240 concentrations) and 815 subjects in three Phase 3 studies (Studies 2093-301, 2093-302, and 2093-304; 1725 concentrations).

**Results:** A 1-compartment model with first-order absorption and elimination reasonably fit these data. Estimated basal eslicarbazepine apparent clearance (CL/F) was 2.43 L/h, with lower (33.8%) eslicarbazepine area under the concentration-time curve at steady state (AUCss) with concomitant administration of phenobarbital/phenobarbital-like metabolic inducers (phenytoin, primidone) or carbamazepine (range: 25.1% - 34.4% for carbamazepine doses of 200 mg twice daily to 400 mg three times daily). Eslicarbazepine CL/F increases with increasing creatinine clearance (CrCL); a hypothetical subject with an estimated CrCL of 80 or 50 mL/min and body weight of 70 kg will have a higher (7.5% and 17.8%) eslicarbazepine AUCss as compared to a hypothetical subject with the median CrCL of 115.7 mL/min and body weight of 70 kg. Eslicarbazepine CL/F increases in proportion to body weight, with AUCss 24.3% higher and 27.5% lower for a hypothetical subject with body weight of 34 or 140 kg, a CrCL of 115.7 mL/min, and not receiving concomitant AEDs relative to the same subject with body weight of 70 kg. Concomitant administration of phenobarbital/phenobarbital-like metabolic inducers (phenytoin, primidone) resulted in higher (19.6%) eslicarbazepine apparent distribution volume (V/F) compared to subjects administered no other AEDs. Female subjects had a slightly lower (16.15%) eslicarbazepine V/F compared to male subjects. The V/F increases with increasing body weight and is predicted to be 47.7, 51.4, and 56.2 L in a hypothetical female subject with a body weight of 62, 70, or 81 kg, and 56.9, 61.3, and 67.1 L for a male subject at the same body weights.

**Conclusions:** This modeling supported individual subject eslicarbazepine exposure estimation for Phase 3 population PK/PD efficacy analyses.

## Introduction

- Eslicarbazepine acetate is a novel single-enantiomer member of the carboxamide family of AEDs.<sup>1</sup>
- Following oral administration, eslicarbazepine acetate is rapidly and extensively metabolized to eslicarbazepine, which represents about 95% of total systemic drug exposure.<sup>2</sup>
- Although the precise mechanism of action is unknown, *in vitro* electrophysiological studies indicate that both eslicarbazepine acetate and eslicarbazepine competitively interact with Site 2 of the inactivated state of a voltage-gated sodium channel.<sup>3,4</sup>
- Maximum plasma concentration (C<sub>max</sub>) of eslicarbazepine is attained approximately 3 hours post dose, with steady state attained after 4 to 5 days of once-daily dosing.<sup>2</sup>
- Eslicarbazepine is eliminated from the systemic circulation, primarily by renal excretion, in the unchanged and glucuronide conjugate forms.<sup>3,5</sup>

## Objective

- Develop a population PK model describing the influence of selected covariates and other AEDs on the PK of eslicarbazepine.

## Methods

### Study Design and Data

- Data were obtained from adult patients enrolled in 11 densely sampled Phase 1 studies and 3 sparsely sampled Phase 3 studies; analysis included only multiple 400-mg to 1200-mg doses administered once daily.
- Subjects randomized to treatment in the Phase 3 trials had at least 4 partial-onset seizures per 4 weeks during the baseline period, were aged 16 years or more, and currently receiving treatment with 1 or 2 AEDs in a stable dose regimen.
- Part I: Each Phase 3 study included an 8-week placebo baseline period, followed by a double-blind 2-week dose titration period, a 12-week maintenance period, and a 4-week tapering off period (1 study only).
- Part II: 1-year open-label extension of two Phase 3 studies, starting with eslicarbazepine acetate 800 mg once daily for 1 month, then allowing for dose titration to 400 mg or 1200 mg once daily in 400-mg increments.
- Part III: an additional 1-year open-label extension in one Phase 3 study, with dose titration as above.
- Sparse PK sampling (trough concentrations) was performed during Part I prior to the baseline period, prior to the first treatment dose, week 8 (1 study only), at the end of maintenance therapy week 12, at the end of the tapering period (1 study only), and during Part II at 1, 6, and 12 months. Full-profile PK sampling was performed (n = 50) during a visit in Part III, and in all Phase 1 studies to 24 hours post dose.
- Plasma samples were analyzed for eslicarbazepine concentrations with chiral liquid chromatography coupled to mass spectrometry (LC-MS/MS) assay. The lower limit of quantitation was 50 ng/mL.

### Data Analysis

- Data preparation was performed using SAS, Version 9.2;<sup>6</sup> the population PK analysis was performed using NONMEM, Version 6, Level 2.0,<sup>7</sup> using the first-order conditional estimation (FOCE) and FOCE with interaction methods.
- The base structural model included estimation of between-patient (interindividual) variability in PK (IIV) parameters and within-patient (residual) variability (RV) in drug concentrations.
- Goodness of fit was assessed using scatterplots of predicted versus measured concentrations and versus weighted residuals, %SEM of the parameter estimates, and changes in the estimates of IIV and RV.
- Model validation was performed using a visual predictive check (VPC) procedure (1000 replicate datasets were simulated with NONMEM using the final model).

### Covariate Analysis

- Stationary covariates assessed were age, height, body weight, body mass index, race, and sex.
- Creatinine clearance<sup>8</sup> was tested as a time-varying covariate.
- Concomitant AEDs tested were carbamazepine, valproate, lamotrigine, topiramate, levetiracetam, phenobarbital, clobazepam, primidone, phenytoin, pregabalin, gabapentin, vigabatrin, zonisamide, clobazam, and tiagabine.
- The effect of concomitant AEDs was analyzed sequentially by presence/absence, and if significant, by the effect of AED dose and/or the effect of AED concentration.
- Bayesian estimates of parameters were generated for each individual subject using the base structural PK model, and were plotted versus each of the subject covariates to identify potential relationships between unexplained variability in PK parameters and covariates.

## Results

### Data Description

- 5965 concentrations from 1039 subjects were available for analysis.
- Demographic characteristics of the subjects are shown in **Table 1**.
- Figure 1** shows dose-normalized eslicarbazepine concentrations versus time relative to dosing.
- Overall, the concurrent AEDs most commonly administered were carbamazepine (40.6%), lamotrigine (20.8%), and valproate (18.2%) as shown in **Table 2**.

### Population PK Model Development


- A 1-compartment model with first-order absorption and elimination was found to be an appropriate fit to these data.
- The estimated basal eslicarbazepine CL/F was 2.43 L/h, V/F was 61.3 L, and first-order absorption t<sub>1/2</sub> was 0.296 h.
- The final model parameters are listed in **Table 3**. All fixed and random effect parameters were estimated with good precision (%SEM ≤ 35%).
- The concomitant administration of phenobarbital or phenobarbital-like metabolic inducers (phenytoin, primidone) resulted in lower (33.8%) eslicarbazepine AUCss compared to subjects administered no other AEDs.

**Table 1. Patient Demographics**

Patient Characteristic	n*	Phase 1	Phase 3	Overall
	<b>224</b>	<b>815</b>	<b>1039</b>	
Mean (SD) <sup>b</sup>		36.17 (12.09)	37.99 (11.97)	37.60 (12.02)
Age (year)				
Median		35.00	37.00	36.00
Minimum, Maximum		18.0, 80.0	16.0, 75.6	16.0, 80.0
Mean (SD)		72.62 (11.69)	72.70 (17.01)	72.69 (16.01)
Weight (kg)				
Median		72.00	71.00	71.00
Minimum, Maximum		48.0, 106.0	34.0, 140.0	34.0, 140.0
Mean (SD)		170.31 (9.35)	168.45 (9.70)	168.85 (9.65)
Height (cm)				
Median		170.00	168.00	169.00
Minimum, Maximum		149.0, 199.9	130.0, 205.0	130.0, 205.0
Mean (SD)		24.77 (3.14)	25.57 (5.52)	25.40 (5.11)
Body mass index (kg/m <sup>2</sup> )				
Median		25.00	24.90	24.90
Minimum, Maximum		16.4, 30.0	15.2, 71.4	15.2, 71.4
Mean (SD)		112.65 (24.41)	118.13 (26.54)	116.95 (26.18)
Baseline creatinine clearance (mL/min)				
Median		111.56	116.60	115.51
Minimum, Maximum		38.9, 160.0	41.1, 160.0	38.9, 160.0
Gender, n (%)				
Male		144 (64.3)	433 (53.1)	577 (55.5)
Female		80 (35.7)	382 (46.9)	462 (44.5)
Caucasian		166 (74.1)	683 (83.8)	849 (81.7)
Black		29 (12.9)	24 (2.9)	53 (5.1)
Asian/Pacific Islander		4 (1.8)	61 (7.5)	65 (6.3)
Other		4 (1.8)	47 (5.8)	51 (4.9)
Unknown		21 (9.4)	0 (0.0)	21 (2.0)
Race, n (%)				
Normal		185 (82.6)	685 (84.0)	870 (83.7)
Mild impairment		36 (16.1)	124 (15.2)	160 (15.4)
Moderate impairment		3 (1.3)	6 (0.7)	9 (0.9)

\* n = number of subjects.  
<sup>b</sup> SD = standard deviation.

**Figure 1. Dose-Normalized Eslicarbazepine Concentrations Versus Time Relative to Dosing, by Study Phase**



**Table 2. Number and Percent of Subjects Taking Concomitant Antiepileptic Drugs**

Concomitant Medications	Phase 1	Phase 3	Overall
Carbamazepine, n (%)	18 (8.0)	404 (49.6)	422 (40.6)
Clobazam, n (%)	0 (0.0)	117 (14.4)	117 (11.3)
Clobazepam, n (%)	0 (0.0)	51 (6.3)	51 (4.9)
Gabapentin, n (%)	0 (0.0)	23 (2.8)	23 (2.2)
Lamotrigine, n (%)	14 (6.3)	202 (24.8)	216 (20.8)
Levetiracetam, n (%)	0 (0.0)	145 (17.8)	145 (14.0)
Phenobarbital, n (%)	0 (0.0)	73 (9.0)	73 (7.0)
Phenobarbital-like, n (%) <sup>a</sup>	15 (6.7)	139 (17.1)	154 (14.8)
Phenytoin, n (%)	15 (6.7)	71 (8.7)	86 (8.3)
Pregabalin, n (%)	0 (0.0)	10 (1.2)	10 (1.0)
Primidone, n (%)	0 (0.0)	6 (0.7)	6 (0.6)
Tiagabine, n (%)	0 (0.0)	8 (1.0)	8 (0.8)
Topiramate, n (%)	13 (5.8)	105 (12.9)	118 (11.4)
Valproate, n (%)	0 (0.0)	189 (23.2)	189 (18.2)
Vigabatrin, n (%)	0 (0.0)	3 (0.4)	3 (0.3)
Zonisamide, n (%)	0 (0.0)	17 (2.1)	17 (1.6)

<sup>a</sup> phenobarbital or phenobarbital-like metabolic inducers (phenytoin, primidone).  
 Note: Some subjects were on >1 concomitant AED.

**Table 3. Parameter Estimates and Standard Errors From the Final Pharmacokinetic Model**

Parameter	Final Parameter Estimate		Magnitude of Interindividual Variability (%CV)	
	Population Mean	%SEM <sup>a</sup>	Final Estimate	%SEM
k <sub>a</sub> (h <sup>-1</sup> )	2.34	9.6	126.49	18.4
CL/F for no carbamazepine use (L/h)	2.43	1.3	27.04	10.5
Additive shift of concomitant phenobarbital or phenobarbital-like inducers (phenytoin, primidone) on CL/F (L/h)	1.24	6.7		
Slope term for effect of body weight on CL/F (L/h/kg)	0.0132	24.0		
Power term for effect of creatinine clearance on CL/F	0.195	33.9		
Additional CL/F when carbamazepine dose = 800 mg (L/h)	1.08	5.4		
V/F (L)	0.411	35.8	17.69	15.6
Power term for effect of carbamazepine dose on CL/F	61.3	2.0		
Additive shift of female gender on V/F (L)	-9.9	18.2		
Additive shift of concomitant phenobarbital or phenobarbital-like inducers (phenytoin, primidone) on V/F (L)	12.0	30.3		
Power term for effect of body weight on V/F	0.617	15.0		
Ratio of additive/proportional RV components <sup>c</sup> (σ <sub>r</sub> <sup>2</sup> /σ <sub>w</sub> <sup>2</sup> ), Phase 1	4520	18.4	NA	NA
Proportional RV component (σ <sub>w</sub> <sup>2</sup> ), Phase 1	0.0124	7.8	NA	NA
Ratio of additive/proportional RV components <sup>c</sup> (σ <sub>r</sub> <sup>2</sup> /σ <sub>w</sub> <sup>2</sup> ), Phase 3	0.0000632	31.6	NA	NA
Additive RV component (σ <sub>w</sub> <sup>2</sup> ), Phase 3	5290000	17.1	NA	NA
Minimum value of the objective function = 99315.706				

<sup>a</sup> %CV = percent coefficient of variation.

<sup>b</sup> %SEM = percent standard error of the mean.

<sup>c</sup> Residual variability in the Phase 1 data was estimated to range from 23.74 %CV to 11.24 %CV at predicted eslicarbazepine concentrations ranging from 2400 ng/mL to 33000 ng/mL, respectively.

<sup>d</sup> Residual variability in the Phase 3 data was estimated to range from 311.15 %CV to 15.68 %CV at predicted eslicarbazepine concentrations ranging from 740 ng/mL to 39200 ng/mL, respectively.

- Subjects administered carbamazepine had a lower eslicarbazepine AUCss (range: 25.1% - 34.4% for carbamazepine doses ranging from 200 mg twice daily to 400 mg three times daily) compared to subjects administered no other AEDs.
- Apparent oral clearance of eslicarbazepine increases with increasing CrCL. A hypothetical subject with an estimated CrCL of 80 or 50 mL/min and a body weight of 70 kg will have a higher (7.5% and 17.8%, respectively) eslicarbazepine AUCss as compared to a hypothetical subject with the median CrCL of 115.7 mL/min and a body weight of 70 kg.
- Eslicarbazepine CL/F increases in proportion to body weight, with AUCss 24.3% higher and 27.5% lower for a hypothetical subject with a body weight of 34 or 140 kg, a CrCL of 115.7 mL/min, and not receiving concomitant AEDs relative to the same subject with a body weight of 70 kg.
- Eslicarbazepine V/F increases with increasing body weight. For a male subject with a body weight of 61, 70, or 79 kg, the V/F of eslicarbazepine is predicted to be 56.9, 61.3, or 67.1 L. These differences are not expected to be clinically relevant.
- The V/F was also increased in subjects treated with phenobarbital or phenobarbital-like metabolic inducers (phenytoin, primidone) by 12.0 L. This increase in V/F is not expected to be clinically relevant.
- The V/F of eslicarbazepine was estimated to be 9.9 L lower in females as compared to males with the same body weight. This small gender difference in V/F is not expected to be clinically relevant.
- The equations to predict the typical CL/F and V/F of eslicarbazepine are shown in **Figure 2**.
- Figure 3** displays goodness-of-fit plots for the final population PK model.

**Figure 2. Population Pharmacokinetic Model Equations**

$$CL/F_j = \left[ 2.43 + 1.08 \times \left( \frac{\text{dose}_{cbz_j}}{800} \right)^{0.411} + 1.24 \times \text{flag}_{phb_j} + 0.0132 \times (\text{wt}_j - 70) \right] \times \left( \frac{CrCL_j}{115.7} \right)^{0.195}$$

$$V/F_j = \left( 61.3 - 9.9 \times \text{flag}_{sexf_j} + 12.0 \times \text{flag}_{phb_j} \right) \times \left( \frac{\text{wt}_j}{70} \right)^{0.617}$$


Where:

- CrCL<sub>j</sub> is the creatinine clearance in the j<sup>th</sup> subject
- CBZ<sub>dosej</sub> is the daily carbamazepine dose in the j<sup>th</sup> subject
- PHB<sub>flagj</sub> is the flag variable for the presence of phenobarbital or phenobarbital-like metabolic inducers in the j<sup>th</sup> subject (0 for no; 1 for yes)
- SEXF<sub>j</sub> is the flag variable for gender of the j<sup>th</sup> subject (0 for male, 1 for female)
- wt<sub>j</sub> is the body weight in the j<sup>th</sup> subject

## References

- Almeida L, Soares-da-Silva P. Eslicarbazepine acetate (BIA 2-093). *Neurotherapeutics*. 2007;4:88-96.
- Almeida L, Falcao A, Maia J, et al. Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young patients. *J Clin Pharmacol*. 2005;45:1062-66.
- Benes J, Parada A, Figueiredo AA, et al. Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide derivatives 48. *J Med Chem*. 1999;42:2582-87.
- Parada A, Soares-da-Silva P. The novel anticonvulsant BIA 2-093 inhibits transmitter release during opening of voltage-gated sodium channels: a comparison with carbamazepine and oxcarbazepine. *Neurochem Int*. 2002;40:435-40.
- Maia J, Almeida L, Falcao A, et al. Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. *Int J Clin Pharmacol Ther*. 2008;46:119-30.
- SAS [computer program]. Version 9.2. Cary, NC: SAS Institute; 2009.
- NONMEM [computer program]. Version 6, Level 2.0. Ellicott City, MD: ICON Development Solutions; 2006.
- Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron*. 1976;16:31-41.


**Figure 3. Goodness-of-Fit Plots**



### Model Validation

- The majority of the observed sparse data fall within the prediction interval as shown in **Figure 4**, as do all of the full-profile samples collected during the PK sub-study in Part III and the Phase 1 studies.
- The proportion of observed data points falling below and above the 5th and 95th percentile prediction interval bounds was 7.55% and 6.02%, respectively.
- Overall, no apparent bias in the model fit is evident in this comparison of the simulated data (based on the model) to the raw data.

**Figure 4. Percentiles of Simulated Data From the Visual Predictive Check of the Final Model Overlaid on the Observed Eslicarbazepine Concentration Data**



## Conclusions

- The PK of eslicarbazepine are described by a 1-compartment model with first-order absorption and linear elimination. The estimated basal eslicarbazepine CL/F was 2.43 L/h, V/F was 61.3 L, and first-order absorption t<sub>1/2</sub> was 0.296 h.
- Eslicarbazepine CL/F was higher in subjects administered concomitant carbamazepine, phenobarbital or phenobarbital-like metabolic inducing agents, and was also shown to increase with increasing body weight or creatinine clearance.
- The population PK model provided the basis to obtain individual steady-state concentration estimates for later exposure-response analyses of eslicarbazepine acetate efficacy in patients with refractory partial epilepsy.